Mid-term effectiveness, safety, and potential predictors of response of upadacitinib in patients with moderate-to-severe atopic dermatitis: a multicenter observational retrospective study
Authors:
- Francisco Javier Melgosa RamosFRFrancisco Javier Melgosa Ramos
- Carlos Abril PérezCPCarlos Abril Pérez
- Santiago Guillén ClimentSCSantiago Guillén Climent
- María Matellanes PalaciosMPMaría Matellanes Palacios
- Juncal Roca GinésJGJuncal Roca Ginés
- Javier Sabater AbadJAJavier Sabater Abad
- Eduardo Bernia PetitEPEduardo Bernia Petit
- Andrés Casanova EsquembreAEAndrés Casanova Esquembre
- Andrea Estébanez CorralesAndrea Estébanez Corrales
- Victor González DelgadoVDVictor González Delgado
Open Access
- 21 April 2025
- journal article
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 100 (3) , 566-569
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Combining treat‐to‐target principles and shared decision‐making: International expert consensus‐based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitisJournal of the European Academy of Dermatology and Venereology, 2024
- Early intervention and disease modification in atopic dermatitis—the current state of the field and barriers to progressJournal of the European Academy of Dermatology and Venereology, 2023
- Upadacitinib effectiveness in moderate‐to‐severe atopic dermatitis: A real‐life multicentre and retrospective studyAustralasian Journal of Dermatology, 2023
- Correction to: Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of ObservationAmerican Journal of Clinical Dermatology, 2023
- Emerging concepts in neuropathic and neurogenic itchAnnals of Allergy, Asthma & Immunology, 2023
- A real‐world Australian experience of upadacitinib for the treatment of severe atopic dermatitisAustralasian Journal of Dermatology, 2023
- Real-Life Effectiveness and Safety of Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A Single-Center 16-Week StudyDermatology and Therapy, 2023
- Upadacitinib for the Treatment of Atopic Dermatitis in a Spanish Cohort—Real Life: Fifty-Two–Week Follow-up ResultsDermatitis®, 2022
- Effectiveness and Safety of Upadacitinib in the Treatment of Moderate-Severe Atopic Dermatitis: A Multicentric, Prospective, Real-World, Cohort StudyDrugs in R&D, 2022
- Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic DermatitisJAMA Dermatology, 2022